Medical Pharmacology: Coronary Artery Disease Practice
Questions Practice
Questions
Click on the correct answer.
Agents which may promote coronary vasodilation:
- beta-blockers
- calcium channel blockers
- both
- neither
Nitric oxide: homeostatic activities:
- cardiovascular tone
- platelet regulation
- gastrointestinal smooth muscle contraction
- A & B
- A, B & C
Nitric oxide: precursor amino acid
- tyrosine
- tryptophan
- arginine
- proline
- phenylalanine
Nitric oxide half-life:
- < 5 seconds
- thirty seconds
- one-minute
- thirty minutes
- > one-hour
Nitric oxide mainly inactivated by:
- NO synthase
- reuptake
- interaction with hemoglobin
- monoamine oxidase
- catechol-O-methyltransferase
Cardiovascular system: nitric oxide effects
- continual NO release associated with flow-induced shear stress
- intermittent NO release associated with pulsatile arterial flow
- significant determinant of pulmonary distribution of cardiac output
- A & C
- A, B & C
Decreased oxygenation
and nitric oxide response:
- increased NO production
- decreased NO production
- no effect on NO production
Comparing arteries
and veins: nitric oxide production
- veins produce more
- arteries produce more
- equal
Nitric oxide
and platelet aggregation and adhesion:
- nitric oxide inhibits platelet aggregation and adhesion
- nitric oxide promotes platelet aggregation and adhesion
- no effect
Probable site
where NO acts as a neurotransmitter:
- neuromuscular junction
- innervation of the corpora cavernosa
- basal ganglia
- Renshaw cell
Involvement of nitric oxide and immune function:
- suppression of macrophage activation by cytokines
- modulation of inflammation
- both
- neither
Clinical uses of nitric oxide
- management of pulmonary hypertension newborn
- adult respiratory distress syndrome
- management of pulmonary hypertension following cardiopulmonary bypass
- B & C
- A, B & C
If you wish to return to the Table of Contents
in ENGLISH, press the RETURN button above. |
Otherwise, if the text is NOT displayed in
English and you are ready to leave this page,
Press here
to return to the Table of Contents
|